Long-term follow-up study results indicate that a cohort of 20 patients with massive rotator cuff tears that were treated with the OrthoSpace InSpace™ system showed improvements in function and pain at 6 weeks, with effects maintained for up to 5 years.
The study is published in the Archives of Orthopaedic and Trauma Surgery. The open-label, single-arm prospective study evaluated use of InSpace, a biodegradable balloon spacer that may be implanted arthroscopically. No complications or unexpected device-related adverse events were recorded.
ArthoCare acquired a 20% stake in OrthoSpace in 2Q13. In 2Q15, Smith & Nephew, acquirer of ArthroCare, participated in financing to support OrthoSpace’s continued market adoption, clinical study programs and entry into emerging markets. In late 4Q16, the company closed a US $7MM equity financing round (again including the support of SNN), with funds in support of an ongoing U.S. Investigational Device Exemption study.
Additionally in late 4Q16, OrthoSpace released initial study results indicating that patients experienced durable improvements in function and reductions in shoulder pain at 12 months, suggesting that InSpace is an effective alternative to existing surgical treatments.
Since EU launch in 2011, >10,000 patients have received treatment with the InSpace system.
Long-term follow-up study results indicate that a cohort of 20 patients with massive rotator cuff tears that were treated with the OrthoSpace InSpace™ system showed improvements in function and pain at 6 weeks, with effects maintained for up to 5 years.
Long-term follow-up study results indicate that a cohort of 20 patients with massive rotator cuff tears that were treated with the OrthoSpace InSpace™ system showed improvements in function and pain at 6 weeks, with effects maintained for up to 5 years.
The study is published in the Archives of Orthopaedic and Trauma Surgery. The open-label, single-arm prospective study evaluated use of InSpace, a biodegradable balloon spacer that may be implanted arthroscopically. No complications or unexpected device-related adverse events were recorded.
ArthoCare acquired a 20% stake in OrthoSpace in 2Q13. In 2Q15, Smith & Nephew, acquirer of ArthroCare, participated in financing to support OrthoSpace’s continued market adoption, clinical study programs and entry into emerging markets. In late 4Q16, the company closed a US $7MM equity financing round (again including the support of SNN), with funds in support of an ongoing U.S. Investigational Device Exemption study.
Additionally in late 4Q16, OrthoSpace released initial study results indicating that patients experienced durable improvements in function and reductions in shoulder pain at 12 months, suggesting that InSpace is an effective alternative to existing surgical treatments.
Since EU launch in 2011, >10,000 patients have received treatment with the InSpace system.
Copy to clipboard 
